Sage Journals: Discover world-class research

Abstract

Axial spondyloarthritis (axSpA) is a group of debilitating, chronic, rheumatic conditions characterized by inflammation and new bone formation, mainly involving the spine and the sacroiliac joints. The lack of biomarkers in axSpA is well known. Despite significant treatment advances in recent years thanks to the introduction of drugs with a new mode of action, such as new biologic and targeted synthetic disease-modifying antirheumatic drugs, no relevant improvement in the identification of disease biomarkers has been achieved. Common parameters, such as erythrocyte sedimentation rate and C-reactive protein, which are routinely used to measure systemic inflammation, are the sole markers available to date and are not adequate to assess disease activity in all patients.

The aim of this study is to review the most promising serum biomarkers that may help treatment decision in axSpA via a proper assessment of disease activity and identification of negative prognostic factors.

Keywords

ankylosing spondylitis anti-drug antibodies axial spondyloarthritis biomarkers disease activity radiographic progression

Introduction

Spondyloarthritis (SpA) is a group of chronic, inflammatory, rheumatic diseases characterized by overlapping clinical signs and symptoms and a common genetic background.¹ Depending on the predominant pattern of clinical symptoms, a primary peripheral or axial involvement can be distinguished.^1,2 Axial spondyloarthritis (axSpA), which mainly affects the spine and the sacroiliac joints (SIJs) and with a symptom onset usually before the age of 45 years, can be further divided into nonradiographic axSpA (nr-axSpA) and radiographic axSpA, the latter also known as ankylosing spondylitis (AS).² If undiagnosed and untreated, long-term outcomes of axSpA are physical and functional permanent damage as well as lifelong disability.^2,3 Importantly, patients with early disease also experience fatigue and functional impairment with subsequent depression.⁴ Reduced social life and working ability result in a poor quality of life with consequent increase in the economic burden of the disease.⁵

Significant steps forward have been taken in the management of axSpA in clinical practice, following the introduction of tumor necrosis factor (TNF)-α inhibitors (TNFi). Patients with axSpA respond quickly to TNFi, which provide an Assessment of Spondyloarthritis International Society response criteria (ASAS40) improvement in about 40% of patients in the first 3–6 months of treatment. Similar response rates have also been observed following treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) targeting interleukin (IL)-17.^6,7 The role of other bDMARDs targeting IL-12/IL-23^8,9 needs further evaluation in axSpA. Furthermore, the targeted synthetic DMARDs (tsDMARDs), which inhibit intracellular signaling molecules such as the Janus kinases (JAK) showed some preliminary promising results and may be approved in a short time in axSpA treatment.^10,11 The introduction of these new targeted treatments allowed a better understanding of the pathogenesis of axSpA, but such improvements were not paralleled by the discovery of new biomarkers. Because of the absence of rheumatoid factor, axSpA has been long considered to have a seronegative property. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), routinely used inflammatory indices, in addition to human leucocyte antigen (HLA) B27, had been considered until now to be the main diagnostic and therapeutic biomarkers in axSpA. ESR and CRP levels are often within the normal range even in the case of very active disease, and are not adequate to monitor all axSpA patients.^12–15 As a result of the growing awareness of the impact of chronic back pain in axSpA patients and of new breakthroughs on etiopathogenetic mechanisms and in the field of genetics thanks to genome-wide association studies, recent studies have investigated novel potential biomarkers of disease activity to identify patients at higher risk for a worse outcome.^16–20 The National Institute of Health Biomarkers and Surrogate Endpoint Working Group have elaborated the definition of biomarker as a “characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes or pharmacological responses to a therapeutic intervention”.²¹ However, clinical characteristics and comorbidities are also important biomarkers toward the definition and diagnosis of axSpA. The Italian board for the TAilored BIOlogic therapy (ITABIO) group attempted to develop an algorithm to guide first- and second-line biological treatments that mainly relies on clinical features of the disease.^22,23 Likewise, the American College of Rheumatology recommendations for spondyloarthritides also take into account comorbidities to select the preferable treatment options.²⁴ In this regard, rheumatologists have to take into account concomitant cardiovascular disease and metabolic syndrome, the desire of a pregnancy, the risk of infections, and importantly the patients’ preference. Furthermore, concomitant skin psoriasis, uveitis and inflammatory bowel disease (IBD) may be used to characterize the disease in SpA. Along with these factors, other characteristics may help to profile the patient with axSpA and to personalize the treatment. Male sex,²⁵ smoking,^26,27 presence of syndesmophytes²⁸ and active inflammatory or post-inflammatory modifications on MRI²⁹ are known predictors of a more severe disease with higher Ankylosing Spondylitis Disease Activity Score (ASDAS) or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and with a radiographic progression.

A large number of biomarkers have been investigated and suggested in axSpA and variable evidence is available on their role in the diagnosis, clinical and prognostic assessment and evaluation of the response to treatment.

The purpose of our review was to summarize the available biomarkers in axSpA towards a more tailored therapeutic approach. Specifically, we focused on markers associated with disease activity and treatment response (clinical and radiological). We performed a PubMed search of articles published between 1984 and 2019. The search terms included: axial spondyloarthritis, ankylosing spondylitis, biomarkers, serological markers, antibodies, immunogenicity. Biomarkers are presented according to five main categories: (1) systemic markers of inflammation; (2) molecules implicated in the bone homeostasis; (3) miscellaneous; (4) anti-drug antibodies (ADAbs) and drug through levels; and (5) combination of biomarkers. A schematic summary of their potential use in axSpA is reported in Table 1.

Table 1.

A schematic summary of the potential use in the clinical practice of selected promising biomarkers in axial spondyloarthritis.

Biomarker	Association with disease activity	Association with treatment response	Predictor of structural damage
Systemic markers of inflammation
CRP	Positive association with disease activity indices^{12,14,18,19,30}	Decreases following treatment response^13,14,19	High levels predict further damage^13,14,19
Erythrocyte sedimentation rate			High levels predict further damage¹³
Calprotectin	Positive association with disease activity indices and structural damage^31–33	Decreases following treatment response^34–36	High levels predict damage³³
Serum amyloid A proteins	Positive association with systemic inflammation^12,37,38	Inconclusive^9,12
Tumor necrosis factor-α	Inconclusive^39,40	Inconclusive^39,40
IL-6	Inconclusive association with disease activity indices;^18,39,41 positive association with structural damage^18,42–45		High levels predict damage^18,45
IL-17	Inconclusive^43,46,47	Decreases following treatment response⁴³
IL-23	Inconclusive^43,47
Molecules implicated in the bone homeostasis
Sclerostin	Negative association with disease activity indices^48,49		Low levels predict damage^50–52
Wnt proteins and Dickkop-1	Inconclusive⁵³		Inconclusive⁵⁴
Osteoprotegerin	Positive association with disease activity indices^51,55,56		Inconclusive^51,55,56
Matrix metalloproteinase 3	Positive association with disease activity indices^57–60	Inconclusive^9,61–63	Inconclusive^45,64,65
Citrullinated fragments of vimentin	Positive association with systemic inflammation^66,67		Inconclusive^66–68
CTX-I and type II collagen	Positive association with systemic inflammation^63,69,70 and structural damage¹⁹ (CTX-II only)	Decreases following treatment response (CTX-II only)^18,19,71	High levels predict damage^63,70,72,73
Osteocalcin			High levels predict damage^14,19,74,75
Miscellaneous
Vascular endothelial growth factor	Positive association with systemic inflammation^76–78		High levels predict damage^76–78
Leptin	Negative association with disease activity indices⁷⁹		Inconclusive results^45,80,81
High-molecular-weight adiponectin			Low levels predict damage⁷⁸
p40 IL-12/23	Serum IL-12p40 levels were raised in AS and correlated with CRP and ASDAS⁸²
Hepatocyte growth factor	Pleiotropic effects in the suppression of inflammation^60,83		Molecule involved in the osteoproliferation and osteoporosis in AS⁸⁴
Anti-drug antibodies and drug through levels
Anti-drug antibodies		In patients with unsatisfactory clinical response, detectable levels may predict treatment failure^85–92 and subsequent good response to another drug with the same mechanism of action⁹³
Drug through levels		In patients with unsatisfactory clinical response, low levels are associated with good response to dose increase⁸⁸
Combination of biomarkers
ENRADAS trial combination biomarker	Positive association with disease activity indices⁷⁸		Inconclusive⁷⁸

AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; CTX-I, C-terminal cross-linking telopeptide of type I; CTX-II, C-terminal cross-linking telopeptide of type II; IL, interleukin.

Systemic markers of inflammation

CRP and ESR, are acute-phase proteins used in clinical practice as markers of systemic inflammation.⁹⁴ Unfortunately, they may not fully represent the inflammatory process in axSpA due to their low sensitivity and specificity.⁹⁵ An elevated CRP is one of the items included in the classification criteria of the ASAS for axSpA.² CRP levels are also taken into consideration in the ASDAS and they were shown to correlate with the BASDAI.⁹⁶ However, elevated CRP or ESR levels are detected in only 40–50% of patients with AS.⁹⁷ In fact, the degree of inflammation fluctuates during the course of axSpA. In general, CRP levels are higher in patients with radiographic axSpA compared with nr-axSpA.³⁰ Although CRP is within the normal range in a large proportion of patients with active axSpA, it is still widely considered a reliable marker of disease activity. In fact, CRP levels are moderately correlated with magnetic resonance imaging (MRI) inflammation.^14,18,19,30 In addition, CRP has been found to be a reliable biomarker for monitoring treatment response and predicting further radiographic progression.^30,98 Several studies have shown that CRP levels drop significantly during TNFi treatment.^13–15 Modifications in CRP levels correlate with changes in BASDAI and MRI scores. Elevated baseline CRP levels are associated with a good treatment response^12,14 and represent a strong positive predictor of radiographic sacroiliitis progression, especially for nr-axSpA into AS.¹⁴ Several prospective studies have also demonstrated that elevated CRP levels are independently associated with radiographic spinal progression in axSpA patients.⁹⁸ The ESR seems to be a nonspecific measure of inflammation that may be influenced by a variety of other nonrheumatic conditions and comorbidities. However, some studies reported that high ESR levels and increased CRP levels are independently associated with structural disease progression in patients with nr-axSpA.¹³

Besides the two most common inflammation markers, calprotectin (CPT) is a promising marker of inflammation that has recently gained interest in several inflammatory rheumatic diseases. CPT is a heterodimeric calcium- and zinc-binding protein complex, composed of S100A8 and S100A9 subunits, expressed in the cytosol of keratinocytes, neutrophils and monocytes. This protein exerts diverse intra- and extracellular functions, acting on different target tissues/organs, such as muscle, cartilage, bone, synovial tissue, vessels and epithelium, among others. Modulation of the inflammatory response by binding to different cell-surface proteins such as Toll-like receptor, as well as oxidant-scavenging, antimicrobial and apoptosis-inducing activities are among the extracellular functions attributed to CPT.⁹⁹ Interestingly, both pro- and anti-inflammatory roles have been reported for CPT.^50,100 Additionally, previous studies showed that CPT is a sensitive and specific biomarker of local inflammation, mirroring intestinal or synovial inflammation. Fecal CPT levels have been associated with disease activity in AS and are associated with inflammatory activity in the bowel.^101–103 Serum CPT levels can be used as a marker of inflammation in nr-axSpA, AS and reactive arthritis without significant difference in the levels between these diseases. Some authors reported that elevated CPT levels positively correlated with ESR, CRP, BASDAI, and ASDAS as well as Spondyloarthritis Research Consortium of Canada (SPARCC) scoring.^31,32 CPT might also be used to monitor treatment response. Serum levels of CPT were reported to decrease following treatment with TNFi.^34,35 S100A8 and S100A9 subunits were reduced after 6 weeks of IL-17 inhibition with secukinumab and correlated with ASAS response.³⁶ A significant decrease in serum CPT was noted also after intensive physiotherapy in patients with nr-axSpA and AS.¹⁰⁴ Serum CPT has a potential role as a prognostic factor, being associated with radiographic spinal progression.³³ Baseline CPT serum levels have been found significantly increased in patients with a higher modified Stoke Ankylosing Spondylitis Spinal Scores (mSASSS) versus those without.³³ A few studies reported an association of CPT with adverse lipid profiles, in addition to the known association with classical inflammatory biomarkers, which strengthens the association between inflammation and development of atherosclerosis and may help to identify patients with axSpA at high risk of cardiovascular events.^55,105–107

Serum amyloid A (SAA) protein was also suggested to help in disease monitoring although it is less reliable compared with CPT. SAA is a family of apolipoproteins associated with high-density lipoproteins that are produced in response to an inflammatory trigger. Patients with AS have higher serum SAA levels with respect to healthy controls; SAA levels also correlated with inflammatory markers and disease activity variables.^12,37,38 Similarly to CRP, baseline high SAA levels were shown to be associated with higher odds of treatment response to TNFi, especially in patients with elevated CRP.¹² SAA levels were decreased following treatment with ustekinumab, and anti-IL-12/23, in patients with AS; however, no correlation with clinical response was observed.⁹

Cytokines are key mediators in the pathogenesis of rheumatic diseases. However, their role as biomarkers are widely debated. TNF-α has long been the only cytokine known to be involved in the pathogenesis of axSpA, leading to the development of therapeutic antibodies targeting this cytokine. Notably, TNF-α provides a potential link between inflammatory response and disturbed bone homeostasis,³⁹ exerting several effector and biological functions via proinflammatory cytokines and chemokine release, the activation of endothelial cells with upregulation of adhesive molecules, leucocyte accumulation, angiogenesis, lymphocyte activation, fibroblast proliferation and chondrocyte and osteoclast activation. TNF-α expression is strongly upregulated in SIJ biopsies of patients with AS⁴⁰ and serum levels are significantly higher in patients with AS compared with subjects with noninflammatory back pain or healthy controls.^39,108 In addition to the interesting findings that support TNF-α involvement in the disease, the serum levels did not prove to be reliable biomarkers of disease activity.

IL-6, similarly to TNF-α, is one of the most extensively studied cytokine in rheumatic diseases, especially in rheumatoid arthritis (RA), but it has also been evaluated in axSpA. IL-6 is produced by a variety of immune cells that further induce the production of several acute-phase proteins.³⁹ IL-6 is involved in the very early stage of the inflammation process by inducing the gathering of neutrophils at the inflammation site and modulating T-cell activation and differentiation. Elevated IL-6 levels were also found to be expressed in cartilage, synovial fluid and connective tissue in SIJ biopsies of patients with AS, particularly in early stages.¹⁰⁹ Higher IL-6 serum levels are usually found in patients with AS compared with healthy controls.^39,110,111 An association between IL-6 serum levels and activity indices or inflammatory markers was demonstrated by some authors,^39,41–43 but was not confirmed by others.^18,44 Particularly, IL-6 does not seem to be associated with other emerging cytokines in the pathogenesis of axSpA, that is, IL-17 and IL-23.¹¹² Notably, IL-6 is associated with MRI changes. Lower baseline levels were found to be associated with lower MRI inflammation scores following TNFi treatment.^18,45 Interestingly, the change of IL-6 levels from baseline to week 4 and week 14 was associated with spinal inflammation in MRI. IL-6 appears to have a potential prognostic role, as high baseline levels were predictive of a high probability of structural response to TNFi as assessed with mSASSS.⁴⁵

Following the introduction of biologics with new modes of action, the interest moved to other cytokines, namely IL-17 and IL-23, which are the targets of these drugs. Both of them are involved in the helper T cell type 17 (T_H17) pathway and are often tested together due to their tight connection. In fact, IL-17 is mainly produced by T_H17 following IL-23 production. The IL-23–IL-17 immune axis is implicated in the pathogenesis of axSpA,^{9,80,113–115} particularly at the entheseal level.^116–118 Most studies reported elevated IL-17 and IL-23 levels in the plasma and serum of patients with AS.^{9,46,47,69,110,116,119} The association with clinical variables is not consistently reported in all studies. IL-17 and peripheral T_H17 cells are reported to be reduced following successful TNFi treatment⁴³ and IL-17 correlates with CRP and disease activity indices, such as BASDAI.^43,46 Other authors failed to find correlation between IL-17 levels and inflammatory indices, disease activity or MRI changes.^46,47 Very similar findings have been found for IL-23 in the same studies.^43,46 Chen et al., showed that IL-17 and IL-23 performed even better compared to ESR and CRP in discriminating patients with disease activity, assessed by BASDAI.⁴⁶

In addition to the above discussed cytokines, IL-21 and IL-22, both linked to IL-17 and T_H17 cells, are elevated in patients with AS.^46,120–122 IL-22 was strongly associated with IL-23 in one study, but no associations with clinical, serological and imaging variables were found.¹¹⁹ IL-31 emerged as the only cytokine to be higher in patients with SpA compared with controls in a French cohort, and it was associated with less structural damage.¹¹² IL-33, a member of the IL-1 family, was found to be elevated in the serum of patients with AS in China and to correlate with disease activity or other inflammatory markers.^123–125

Molecules involved in bone homeostasis

Molecules mirroring bone metabolism that can be detected in the serum represent an opportunity to better understand and monitor axSpA. Molecules driving bone resorption and formation and enzymes degrading extracellular matrix are among the best studied. Components of the extracellular matrix and its degradation products have been extensively studied in the field of osteoporosis and associations between their serum levels with axSpA disease activity have also been investigated.

The human receptor activator of nuclear factor-κB ligand (RANKL) and monocyte colony-stimulating factor (M-CSF) are the two key molecules involved in osteoclast formation from peripheral blood monocytes and in osteoclast activation¹²⁶ and are the best studied. These cytokines play a critical role in physiological bone turnover and their dysregulation leads to impairment of osteoclast generation and excessive bone formation, as observed in several rheumatic diseases, including SpA. However, there is substantial discrepancy regarding serum RANKL levels in patients with SpA (especially axSpA). Some studies reported either higher or lower serum RANKL levels in patients with axSpA in comparison to healthy subjects.^{48,51,127,128}

Sclerostin (SOST) is a bone morphogenic protein antagonist. SOST, being an antagonist of the Wnt/β-catenin pathway, exerts anti-anabolic effects on bone formation and a reduced biological effect of SOST seems responsible for the bone neo-ossification that is typical of AS.¹²⁹ Nonetheless, studies focusing on SOST levels in patients with AS gave diverging results. Most of the studies found lower levels in individuals with AS compared with controls,^50,56,64 and an association with disease activity was found.^49,51 Some studies also suggested a prognostic value, as low baseline SOST levels in AS and axSpA were associated with new syndesmophyte formation.^50–52 Interestingly, anti-SOST antibodies were found together with low SOST levels, thereby implying a possible pathogenic role of the antibodies neutralizing SOST.^130,131

The Dickkopf (Dkk) proteins are one of the two main families of soluble inhibitors of the Wnt proteins, and include the most important protein, Dkk-1. The activation of Wnt signaling induces osteoblastogenesis and is implicated in new bone formation. As Dkk-1 is an inhibitor of the Wnt pathway, one might expect Dkk-1 concentrations to be low in the diseases characterized by an increase of new bone formation. Nevertheless, only a few studies found lower Dkk-1 levels in patients with AS.^74,132 Furthermore, consistently with most other studies, Dkk-1 concentrations were higher in patients with AS compared with healthy subjects,^{54,55,133,134} similarly in patients with peripheral SpA compared with healthy controls; and higher in patients with AS compared with psoriatic arthritis (PsA).¹³³ Thus, it has been suggested that Dkk-1 serum levels may be higher in axial disease because of a pathologically dysfunctional Dkk-1 molecule, which does not inhibit Wnt-mediated osteoproliferation in axSpA. In fact, possible explanations are provided by the observation that Dkk-1at high levels binds to its receptor LRP6 with low avidity in AS,^54,133 and that Dkk-1 even has a stimulatory effect on the Wnt pathway in the presence of anti-Dkk-1 monoclonal antibodies.¹³³ Dkk-1 is not correlated with CRP level,⁵³ and TNFi treatment does not affect Dkk-1 levels.⁵⁴ The latter observation may be unexpected because recent data showed a retardation of radiographic progression under TNFi in different patient groups (e.g. with treatment initiation within the first 10 years after symptoms,¹³⁵ after long-term treatment¹³⁶ or in the case of a good treatment response¹³⁷).

Osteoprotegerin (OPG), a member of the TNF receptor superfamily, inhibits the RANK–RANKL interaction, impeding osteoclastogenesis with anti-resorptive effects. Several studies found OPG levels higher in patients with AS compared with controls,^8,55,127,138 whereas others found the opposite.^51,56 OPG seems to correlate with BASDAI score, being higher in patients with more active disease, but not with TNFi treatment response.^51,55,56

Matrix metalloproteinases (MMPs) are relevant enzymes involved in the degradation of extracellular matrix proteins. These zinc-dependent endopeptidases also play a role in cell proliferation, migration, differentiation, angiogenesis, apoptosis and host defence.^139–141 MMP-3 is the most studied among these molecules in axSpA. MMP-3 serum levels are increased in patients with AS with respect to healthy controls.^139–141 Furthermore, some investigators have reported that MMP-3 correlated with ESR and CRP levels, disease activity and functional status, as assessed by the BASDAI.¹⁴² Similar findings have been also found in PsA, further confirming the potential role of this molecule as a biomarker.^57–59 TNFi induce a significant and rapid decrease in serum MMP-3 levels together with a reduction in conventional variables (ESR and BASDAI).^61–63 A similar effect was observed after treatment with ustekinumab, although MMP-3 decrease was not associated with clinical variables.⁹ MMP-3 association with structural damage has been reported.^64,143 Maksymowych et al. showed that MMP-3 was a significant independent predictor of radiographic progression over a 2-year observation period in axSpA,¹⁴³ suggesting that MMP-3 could be considered a parameter of bone metabolism. Other studies did not confirm the association of MMP-3 with inflammation in the SIJs detected by MRI,¹⁴⁴ with radiographic progression.^45,65 Although fewer studies have been carried out on other MMPs, MMP-8 and MMP-9 (but not MMP-3) were found to be associated with disease activity, as assessed by the BASDAI score.⁶⁰

Cathepsin K is a potent collagenase predominantly expressed in osteoclasts and is involved in bone remodeling and resorption. Cathepsin K expression follows the signal of inflammatory cytokines released after tissue injury. Reports of cathepsin K levels in AS are controversial; this molecule seems to be expressed at a higher level by mononuclear cells, fibroblast-like cells, and other cells attached to bone but cathepsin K serum levels were not different compared with healthy controls and no significant modification following TNFi was observed.^145,146

The cartilage oligomeric matrix (COMP) protein catalyzes the assembly of collagen in the extracellular matrix. Elevated COMP levels were observed in a variety of inflammatory joint diseases;¹⁸ however, its association with other clinical and disease activity markers in AS have been inconsistently reported. Nevertheless, one study reported an inverse relationship between COMP levels and MRI inflammation in patients with axSpA.¹⁹ Bone-specific alkaline phosphatase (BAP) is a marker of active bone formation. High levels of BAP have been found in patients with axSpA and are associated with disease activity.^53,64

Recently, extracellular matrix turnover products have gained interest as possible biomarkers in SpA. Citrullinated fragments of vimentin (VICM) are MMP-degraded fragments modified by citrullination, a process occurring unspecifically during the inflammatory phase. VICM was found to be higher in patients with AS compared with controls and to be associated with high CRP serum levels.^66,67 VICM levels, together with high baseline mSASSS values, were found to be predictors of radiographic progression.⁶⁶ However, other researchers did not confirm this finding.^67,68 Furthermore, indirect biomarkers of VICM, anti-citrullinated vimentin antibodies, are higher in SpA, including individuals with AS versus controls and appeared to show promising molecules associated with radiographic damage and correlated with CRP.⁶⁵

Other products of collagen degradation are fragments of type I (C1M), II (C2M), IV (C4M), V (C5M), and VI (C6M) collagens generated by MMP. Their high levels in AS, compared with controls, supports their association with tissue remodeling during active disease.^66,147,148 C1M and C6M are also correlated with CRP.^65,66 C1M was associated with mSASSS progression in one study; however, the association was not confirmed after adjustment for confounders.⁶⁷ A combination of C2M, C3M and C6M was found to be a marker of structural progression as it correlated with mSASSS.⁶⁶ More recently C1M, C5M and C6M showed no relationship with mSASSS progression.⁶⁸

An MMP-mediated metabolite of CRP (CRPM) was found to have higher levels in AS compared with nr-axSpA and was associated with some disease activity indices, such as CRP and ASDAS-CRP.⁶⁵

Type I and type II collagen are proteins of cartilage and components of connective tissue. Studies have evaluated both serum and urinary type I and II C-terminal telopeptides (CTX-I and CTX-II). CTX-I is a marker of osteoclast activity reflecting bone degradation.¹⁴⁹ Both urinary and serum CTX-I levels are higher in patients with AS compared with healthy controls.^72,150 CTX-II levels were shown to correlate with MRI inflammation scores in SIJs and/or lumbar spine in patients with axSpA .¹⁹ CTX-II serum levels were also correlated with serological markers of disease activity,^63,70,72 and they decreased after treatment with TNFi.^18,19,71 CTX-II seems to be a biomarker of radiographic progression in axSpA. In multivariate analyses with a 2-year change in mSASSS,⁷⁰ CTX-II seems to significantly and independently contribute to explaining variation in radiological damage and progression and the association remained after the adjustment for markers of inflammation (which also correlated with CTX-II). This observation suggests that cartilage degradation might be related to the process of syndesmophyte formation. Notably, CTX-II and CTX-I may serve as prognostic markers to identify patients prone to radiographic spinal progression with a more robust evidence for CTX-II.^63,70,72,73

Osteocalcin is a small molecule of the mineralized bone matrix. Previous studies have shown that osteocalcin serum levels in AS are lower than in controls;¹⁵¹ however, recent studies have reported high serum levels in AS, associated with radiographic progression, especially for the development of new syndesmophytes.^14,19,74,75 Osteocalcin was also found to increase early following TNFi treatment,¹⁹ which is intriguing because recent data showed a retardation of radiographic progression under TNFi.

Serum human cartilage glycoprotein-39 (YKL-40), a secretory protein of human articular chondrocytes and synoviocytes, is a marker of cartilage remodeling and is associated with disease activity in AS.¹⁸ YKL-40 serum levels are significantly higher in patients with SpA with respect to healthy controls but YKL-40 does not seem to perform as well as other inflammatory biomarkers, such as CRP and MMP-3, in the disease assessment.¹¹¹ Aggrecan is the central component of cartilage extracellular matrix. The replacement of the glycosaminoglycan side chain with aggrecan with charge density modification determines osmotic processes, which are fundamental for the biomechanical properties of cartilage. Patients with AxSpA have been found to have decreased levels of total aggrecan compared with healthy subjects and aggrecan seems to increase following TNFi treatment.¹⁸

Miscellaneous

Vascular endothelial growth factor (VEGF) is a driver of angiogenesis and seems to be implicated in the initial phase of bone remodeling, which is characterized by inflammation and leads to bone formation. VEGF serum levels were reported to be higher in patients with AS and axSpA than in controls.^{18,70,76,77,123} High VEGF serum levels are associated with active disease and worse radiographic progression according to mSASSS.^59,76–78

The fetuin family encompasses a series of proteins that have been implicated in numerous biological functions. Particularly, fetuin proteins seem to play a role in inflammatory processes and are implicated in bone remodeling, osteogenesis and bone resorption.¹⁵² Fetuin-A was found to be higher in patients with AS with syndesmophytes compared with patients with AS without syndesmophytes or controls.¹⁵³

Adipokines are cytokines secreted by adipose tissue, which also have a role in mediating immune responses and regulating bone mass. Leptin, visfatin and high-molecular-weight adiponectin (HMW-ADN) are those mostly investigated in axSpA; however, inconsistent results have been reported. Leptin serum levels in AS have been reported to be either higher^154,155 or lower compared with controls.^78,81 A negative association of leptin with BASMI⁷⁹ has been found and with radiographic progression independently of CRP and baseline structural damage,^80,81 but other authors did not confirm this association.⁴⁵ HMW-ADN serum levels were also found to be reduced in AS compared with controls and they were associated with syndesmophyte formation.⁷⁸ Visfatin is reported to be increased compared with controls and seems to be associated with radiographic spinal progression, like resistin.¹⁵⁶

Cytotoxic T lymphocyte-associated molecule (CTLA-4) is an inhibitor of immune response. CTLA-4 serum levels were lower in healthy controls compared with patients with axSpA, where they were correlated with CRP and BASDAI.¹⁵⁷

Recently, anti-CD74 antibodies (or anti-CLIP antibodies) directed against CD74, a class II-associated invariant chain peptide, were found in patients with axSpA.¹⁵⁸ Binding of CLIP antibodies to CD74 may lead to activation of cells and production of proinflammatory cytokines such as TNF-α. Baraliakos et al.¹⁵⁹ found anti-CLIP antibodies are mostly present in patients with early axSpA compared with controls, but the frequency of such antibodies decreases overtime¹⁵⁸ and further studies did not confirm a significant diagnostic value in patients suffering with inflammatory low back pain.¹⁶⁰

Some researchers considered the possible role of p40 subunit, common to IL-12 and IL-23, as a biomarker of disease activity, as higher levels of synovial p40 IL12/23 were found higher in 27 patients with SpA versus patients with osteoarthritis and versus paired serum SpA levels.¹⁶¹ Ivanova et al. reported that serum IL-12 and IL-23p40 were raised among patients with AS and correlated with CRP and ASDAS;⁸² however, the findings warrant further confirmation in larger cohort studies.

Two reports have also recently described the hepatocyte growth factor (HGF) as a promising biomarker.^60,83 HGF is secreted by mesenchymal cells and has pleiotropic effects, including suppression of inflammation and enhanced osteoblastic differentiation of mesenchymal cells. HGF appears to be involved in the osteoproliferation and osteoporosis in AS.⁸⁴ Consistent associations between HGF and parameters of bone remodeling and lesions on imaging, especially on MRI, have yet to emerge.

Anti-drug antibodies and drug through levels

Immunogenicity has been implicated as a cause of treatment failure of bDMARDs, as all biological drugs have immunogenic potential^85,162,163 and may induce formation of ADAbs. ADAb development is well known in RA and IBD, and it is described in all patients treated with monoclonal antibodies.¹⁶⁴ ADAbs are associated with reduced effectiveness of treatments and adverse events and correlated negatively with drug serum levels.¹⁶⁵ A considerable proportion of patients with axSpA treated with TNFi fail to respond ab initio (primary failure), or lose response over time despite an initial good response (secondary failure).^164,166 Some patients may also discontinue TNFi treatment due to significant adverse events.^86,167 ADAbs reduce drug blood levels by neutralizing the binding sites of the target molecules, or by forming immune complexes with the biological drugs and enhancing their clearance.^168–171 ADAbs are described during treatment with all five TNFi to varying degrees, depending on the specific TNFi,¹⁷¹ and also following secukinumab and ustekinumab treatments.^172,173 A comprehensive literature search using three databases (PubMed, Web of Science, and the Cochrane Library) on immunogenicity of TNFi in autoimmune diseases between 1966 and 2017, showed that ADAbs are present in 10% of patients with SpA treated with a TNFi.⁸⁶ In these patients, lower drug through levels are also found, which are usually associated with poorer clinical response.^85–89

ADAbs are often found in patients presenting secondary failure to the treatment and their detection predicted treatment failure over time.^85,87,88,174 Overall, these observations led to the use of such biomarkers to drive treatment decisions, firstly in IBD, due to limited biological drug choice, and then in RA and SpA. Algorithms have been developed to identify TNFi poor responders and to drive treatment decisions, especially after the failure of a TNFi.^90,91 In some studies, in patients with ADAbs and suboptimal treatment response the drug dosage was increased successfully to achieve a better treatment effectiveness.⁸⁸ More recently, the detection of ADAbs was used to identify patients more prone to successfully taper the biological treatment.⁹² In patients with insufficient response, detectable ADAbs and low TNFi levels, we can assume that the drug effect is impaired by ADAbs (Figure 1). Thus, switching to another TNFi may be beneficial as it restores the TNF-α blockade. Nonetheless, if ADAbs are absent or low and the adequate therapeutic levels of the TNFi are achieved, inefficacy is not due to the neutralization of the therapeutic effect, but due to the fact that probably in that patient, TNF-α is not the main pathogenetic cytokine.⁹⁰ Therefore, in the latter, patients switching to another mode of action might be the best treatment choice. The large experience in RA confirms these observations, and also suggests that testing drug levels might be sufficient.^91,175,176 One study on a small cohort of patients with SpA also found that in patients starting a second TNFi, those who had developed ADAbs on the first TNFi showed a better ASDAS response.⁹³

Figure 1.

Possible pathogenetic mechanisms of secondary inefficacy to TNFα treatment. ADAbs, anti-drug antibodies; TNFα, tumor necrosis factor α

In addition to ADAbs, there are other factors that affects the pharmacokinetics of TNFi, such as concomitant use of conventional DMARDs, especially methotrexate, the degree of systemic inflammation, body weight, and sex.¹⁷⁴ Combination therapy with biologic agent and DMARDs is used to prevent the development of ADAbs in patients with RA and IBD,^86,89,177 but there is no evidence to support their use in axSpA.^178,179 Noteworthy, some studies also evaluated immunogenicity of switching from innovator to biosimilar infliximab in patients with SpA¹⁸⁰ and, as expected, it was not associated with any significant difference in the anti-drug antibody level.¹⁸⁰

Combination of biomarkers

In rheumatic diseases, the need for biomarkers has led to several attempts to identify an index including a panel of biomarkers to be used for clinical assessment. In SpA, only two studies are available to date. The first was conducted in a large cohort of 356 patients with SpA treated with golimumab. The study considered 73 molecules potentially associated with structural damage as assessed with mSASSS over a 2-year follow up, and found that only IL-6 was correlated with MRI changes.⁴⁵ Rademacher and colleagues,⁷⁷ considered 117 patients treated with nonsteroidal anti-inflammatory drugs in the ENRADAS trial. Only 10 biomarkers were investigated: VEGF, leptin and HMW-ADN were associated with mSASSS changes after 2 years (the latter two were inversely correlated with mSASSS). The combination of these three biomarkers with clinical characteristics proved to be superior than the clinical variables alone, but with a small added value in predicting structural damage.

Conclusion

Numerous studies have been conducted to seek biomarkers to guide treatment in SpA and to monitor the disease. Currently, no new biomarkers satisfy the characteristics for use in clinical practice and CRP remains the most relevant biomarker in axSpA. Grouping and understanding the role of all other potential biomarkers is challenging. Inflammatory markers, such as CPT, have been investigated but standardization is lacking and they mirror CRP. Markers of bone metabolism, such as MMP and Dkk-1, have shown diverging results on disease activity and progression. The reason could be that biomarkers implicated in the axSpA pathogenetic process are restricted to specific tissues and endothelial compartments and do not migrate to the systemic circulation and/or lymphoid organs.^127,146 ADAbs and therapeutic drug monitoring are adequate tools to drive treatment decision but are not useful to characterize the patient and identify those prone to more rapid structural damage. Eventually, a combination of biomarkers may be promising, nevertheless association with clinical characteristics is necessary to increase their predictive value. Further research should focus on the most promising biomarkers in order to reduce heterogeneity of observations and better define their role and cut-offs either alone or in combination.

Footnotes

Acknowledgements

The authors would like to express their appreciation to Eric Frank Nde for his assistance in editing the English version of this manuscript.

Author contributions

RR and AD contributed to study design and critical revision. ML and FO contributed to data collection and manuscript drafting. AO, MF and MF contributed to literature revision.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Mariagrazia Lorenzin

References

Sieper

Poddubnyy

. Axial spondyloarthritis. Lancet 2017; 390: 73–84.

Rudwaleit

van der Heijde

Landewé

, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777–783.

Braun

van den Berg

Baraliakos

, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896–904.

Zhao

Radner

Siebert

, et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology (Oxford) 2019; 58: 1746–1754.

de Hooge

Ramonda

Lorenzin

, et al. Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther 2016; 18: 265.

Dubash

Bridgewood

McGonagle

, et al. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol 2019; 15: 123–134.

Blair

. Secukinumab: a review in ankylosing spondylitis. Drugs 2019; 79: 433–443.

Deodhar

Gensler

Sieper

, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 258–270.

Poddubnyy

Hermann

KGA

Callhoff

, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014; 73: 817–823.

10.

Maksymowych

van der Heijde

Baraliakos

, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford) 2018; 57: 1390–1399.

11.

van der Heijde

Deodhar

Wei

, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76: 1340–1347.

12.

De Vries

van Eijk

van der Horst-Bruinsma

, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61: 1484–1490.

13.

Poddubnyy

Rudwaleit

Listing

, et al. Comparison of a high sensitivity and standard C-reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2010; 69: 1338–1341.

14.

Visvanathan

Wagner

Marini

, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67: 511–517.

15.

Lorenzin

Ortolan

Vio

, et al. Biomarkers, imaging and disease activity indices in patients with early axial spondyloarthritis: the Italian arm of the spondyloarthritis caught early (SPACE) study. Reumatismo 2017; 69: 65–74.

16.

Prajzlerová

Grobelná

Pavelka

, et al. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 2016; 15: 501–509.

17.

Mohan

Assassi

. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? BMJ 2015; 351: h5079.

18.

Pedersen

Sørensen

Garnero

, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011; 70: 1375–1381.

19.

Pedersen

Sørensen

Lambert

RGW

, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 2011; 63: 3789–3800.

20.

Reveille

. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol 2015; 34: 1009–1018.

21.

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.

22.

Cantini

Niccoli

Nannini

, et al.; Italian board for the TAilored BIOlogic therapy. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 2016; 45: 519–532.

23.

Cantini

Niccoli

Nannini

, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 2017; 47: 183–192.

24.

Singh

Guyatt

Ogdie

, et al. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken) 2019; 71: 2–29.

25.

Ramiro

Stolwijk

van Tubergen

, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015; 74: 52–59.

26.

Poddubnyy

Haibel

Listing

, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis inception cohort (GESPIC). Ann Rheum Dis 2013; 72: 1430–1432.

27.

Zhao

Jones

Macfarlane

, et al. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR biologics register for ankylosing spondylitis (BSRBR-AS). Rheumatology (Oxford) 2019; 58: 811–819.

28.

van Tubergen

Ramiro

van der Heijde

, et al. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2012; 71: 518–523.

29.

Machado

Baraliakos

van der Heijde

, et al. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2016; 75: 1486–1493.

30.

Lorenzin

Ortolan

Frallonardo

, et al. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 2015; 16: 166.

31.

Huang

Yin

Song

, et al. Discriminating value of calprotectin in disease activity and progression of nonradiographic axial spondyloarthritis and ankylosing spondylitis. Dis Markers 2017; 2017: 7574147.

32.

Oktayoglu

Bozkurt

Mete

, et al. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med 2014; 62: 880–884.

33.

Turina

Sieper

Yeremenko

, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 2014; 73: 1746–1748.

34.

Turina

Yeremenko

Paramarta

, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther 2014; 16: 413.

35.

Turina

Yeremenko

van Gaalen

, et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the spondyloarthritis caught early (SPACE) cohort. RMD Open 2017; 3: e000319.

36.

Baeten

Baraliakos

Braun

, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1705–1713.

37.

Lange

Boss

Teichmann

, et al. Serum amyloid A–an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000; 19: 119–122.

38.

van Eijk

de Vries

Levels

JHM

, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324–1330.

39.

Bal

Unlu

Bahar

, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26: 211–215.

40.

Braun

Bollow

Neure

, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499–505.

41.

Musacchio

Valvason

Botsios

, et al. The tumor necrosis factor-α-blocking agent infliximab inhibits interleukin 1β (IL-1β) and IL-6 gene expression in human osteoblastic cells. J Rheumatol 2009; 36: 1575–1579.

42.

Romero-Sanchez

Jaimes

Londoño

, et al. Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin Exp Rheumatol 2011; 29: 828–834.

43.

Xueyi

Lina

Zhenbiao

, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy. J Clin Immunol 2013; 33: 151–161.

44.

Sveaas

Berg

Provan

, et al. Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 2015; 44: 118–124.

45.

Inman

Baraliakos

Hermann

KGA

, et al. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther 2016; 18: 304.

46.

Appel

Maier

Bleil

, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013; 65: 1522–1529.

47.

Chen

Chang

Lin

, et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 2012; 75: 303–308.

48.

Kim

Lee

Kim

. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 2006; 45: 1197–1200.

49.

Nocturne

Pavy

Boudaoud

, et al. Increase in Dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR cohort. PLoS ONE 2015; 10: e0134974.

50.

de Andrade

de Castro

GRW

Vicente

, et al. Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis. Int Immunopharmacol 2014; 21: 481–486.

51.

Taylan

Sari

Akinci

, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012; 13: 191.

52.

Saad

CGS

Ribeiro

ACM

Moraes

JCB

, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012; 14: R216.

53.

Heiland

Appel

Poddubnyy

, et al. High level of functional Dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71: 572–574.

54.

Yucong

Shengfa

, et al. Serum functional Dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab 2014; 60: 1527–1531.

55.

Genre

López-Mejías

Miranda-Filloy

, et al. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2014; 32: 640–646.

56.

Franck

Meurer

Hofbauer

. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004; 31: 2236–2241.

57.

Moz

Aita

Basso

, et al. Spondyloarthritis: matrix metalloproteinasesas biomarkers of pathogenesis and response to tumor necrosis factor (TNF) inhibitors. Int J Mol Sci 2017; 18: 830.

58.

Fiocco

Sfriso

Oliviero

, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther 2010; 12: R148.

59.

Ramonda

Modesti

Ortolan

, et al. Serological markers in psoriatic arthritis: promising tools. Exp Biol Med (Maywood) 2013; 238: 1431–1436.

60.

Mattey

Packham

Nixon

, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther 2012; 14: R127.

61.

Maksymowych

Fitzgerald

Wells

, et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009; 36: 1792–1799.

62.

van Kuijk

AWR

DeGroot

Koeman

, et al. Soluble biomarkers of cartilage and bone metabolism in early proof-of-concept trials in psoriasic arthritis: effects of adalimumab versus placebo. PLoS One 2010; 5: e12556.

63.

Arends

van der Veer

Groen

, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 2011; 38: 1644–1650.

64.

Appel

Ruiz-Heiland

Listing

, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60: 3257–3262.

65.

Siebuhr

Hušáková

Forejtová

, et al. Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clin Exp Rheumatol 2019; 37: 358–366.

66.

Bay-Jensen

Karsdal

Vassiliadis

, et al. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum 2013; 65: 972–980.

67.

Siebuhr

van der Heijde

Bay-Jensen

, et al. Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix? RMD Open 2018; 4: e000648.

68.

Hušáková

Bay-Jensen

Forejtová

, et al. Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. Sci Rep 2019; 9: 11218.

69.

Wang

Lin

Wei

, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009; 29: 1343–1347.

70.

Vosse

Landewé

Garnero

, et al. Association of markers of bone and cartilage degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 1219–1222.

71.

Maksymowych

Rahman

Shojania

, et al.; M03-606 Study Group. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008; 35: 2030–2037.

72.

Park

Chung

Park

, et al. Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 2008; 49: 288–294.

73.

Kang

Jung

Hong

, et al. Positive correlation between inflammation on sacroiliac joint MRI and serum C-terminal telopeptide of type-I collagen in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 2017; 35: 415–422.

74.

Kwon

Lim

Suh

, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012; 32: 2523–2527.

75.

Yilmaz

Ozaslan

. Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000; 19: 92–98.

76.

Poddubnyy

Conrad

Haibel

, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2014; 73: 2137–2143.

77.

Drouart

Saas

Billot

, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003; 132: 158–162.

78.

Rademacher

Tietz

, et al. Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology (Oxford) 2019; 58: 1556–1564.

79.

Sari

Demir

Kozaci

, et al. Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 1427–1432.

80.

Kavanaugh

Puig

Gottlieb

, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 2016; 75: 1984–1988.

81.

Hartl

Sieper

Syrbe

, et al. Serum levels of leptin and high-molecular-weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Res Ther 2017; 19: 140.

82.

Ivanova

Manolova

Miteva

, et al. Genetic variations in the IL-12B gene in association with IL-23 and IL-12p40 serum levels in ankylosing spondylitis. Rheumatol Int 2019; 39: 111–119.

83.

Maksymowych

. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol 2019; 10: 305.

84.

Torres

Klingberg

Nurkkala

, et al. Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis. Osteoporos Int 2019; 30: 441–449.

85.

Mok

van der Kleij

Wolbink

. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 2013; 32: 1429–1435.

86.

Thomas

Borazan

Barroso

, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015; 29: 241–258.

87.

Bornstein

Lidar

Langevitz

, et al. The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018; 36: 228–232.

88.

Arstikyte

Kapleryte

Butrimiene

, et al. Influence of immunogenicity on the efficacy of long-term treatment with TNF α blockers in rheumatoid arthritis and spondyloarthritis patients. Biomed Res Int 2015; 2015: 604872.

89.

Garcês

Demengeot

Benito-Garcia

. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947–1955.

90.

Sirotti

Generali

Ceribelli

, et al. Personalized medicine in rheumatology: the paradigm of serum autoantibodies. Auto Immun Highlights 2017; 8: 10.

91.

l’Ami

Krieckaert

Nurmohamed

, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018; 77: 484–487.

92.

Almirall

Gimeno

Salman-Monte

, et al. Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy. Rheumatol Int 2016; 36: 575–578.

93.

Plasencia

Pascual-Salcedo

García-Carazo

, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther 2013; 15: R79.

94.

Spoorenberg

van der Heijde

de Klerk

, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980–984.

95.

Ruof

Stucki

. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966–970.

96.

Rudwaleit

Landewé

van der Heijde

, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770–776.

97.

Rudwaleit

Haibel

Baraliakos

, et al. The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009; 60: 717–727.

98.

Poddubnyy

Haibel

Listing

, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64: 1388–1398.

99.

Ometto

Friso

Astorri

, et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood) 2017; 242: 859–873.

100.

Schiopu

Cotoi

. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm 2013; 2013: 828354.

101.

Duran

Kobak

Sen

, et al. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci 2016; 16: 71–74.

102.

van Rheenen

Van de Vijver

Fidler

. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.

103.

Klingberg

Carlsten

Hilme

, et al. Calprotectin in ankylosing spondylitis–frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012; 47: 435–444.

104.

Levitova

Hulejova

Spiritovic

, et al. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther 2016; 18: 275.

105.

Angel

Provan

Fagerhol

, et al. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25: 644–650.

106.

Ramonda

Lo Nigro

Modesti

, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011; 10: 773–778.

107.

Ramonda

Puato

Punzi

, et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 2014; 81: 421–425.

108.

Aita

Basso

Ramonda

, et al. Genetics in TNF-TNFR pathway: a complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy. PLoS One 2018; 13: e0194693.

109.

Francois

Neure

Sieper

, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006; 65: 713–720.

110.

Liu

Zhang

, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med 2015; 8: 17362–17376.

111.

Pedersen

Hetland

Sørensen

, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol 2010; 29: 1301–1309.

112.

Rosine

Etcheto

Hendel-Chavez

, et al. Increase in Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis. Sci Rep 2018; 8: 7731.

113.

Baeten

Sieper

Braun

, et al.; MEASURE 1 Study Group, MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534–2548.

114.

Braun

Baraliakos

Deodhar

, et al.; MEASURE 1 study group. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017; 76: 1070–1077.

115.

Sieper

Deodhar

Marzo-Ortega

, et al.; MEASURE 2 Study Group. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis 2017; 76: 571–592.

116.

Jansen

DTSL

Hameetman

van Bergen

, et al. IL-17-producing CD4⁺ T cells are increased in early, active axial spondyloarthitis including patients without imaging abnormalities. Rheumatology (Oxford) 2015; 54: 728–735.

117.

Raychaudhuri

Saxena

Raychaudhuri

. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 2015; 34: 1019–1023.

118.

Duvallet

Semerano

Assier

, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011; 43: 503–511.

119.

Andersen

Rasmussen

Hvid

, et al. Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int 2012; 32: 387–393.

120.

Korn

Bettelli

Gao

, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484–487.

121.

Xiao

Zhang

Liu

, et al. Higher frequency of peripheral blood interleukin 21 positive follicular helper T cells in patients with ankylosing spondylitis. J Rheumatol 2013; 40: 2029–2037.

122.

Zhang

, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One 2012; 7: e31000.

123.

Lin

, et al. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 2013; 61: 848–851.

124.

Wang

Duan

, et al. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol 2013; 42: 226–231.

125.

Han

Zeng

Liang

, et al. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011; 30: 1583–1588.

126.

Park

Lee

. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells 2017; 40: 706–713.

127.

Chen

Liao

, et al. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 2010; 29: 1155–1161.

128.

Perpétuo

Caetano-Lopes

Vieira-Sousa

, et al. Ankylosing spondylitis patients have impaired osteoclast gene expression in circulating osteoclast precursors. Front Med (Lausanne) 2017; 4: 5.

129.

Wijenayaka

Kogawa

Lim

, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011; 6: e25900.

130.

Luchetti

Ciccia

Avellini

, et al. Sclerostin and antisclerostin antibody serum levels predict the presence of axial spondyloarthritis in patients with inflammatory bowel disease. J Rheumatol 2018; 45: 630–637.

131.

Tsui

FWL

Tsui

Las Heras

, et al. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 2014; 73: 1873–1879.

132.

Diarra

Stolina

Polzer

, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156–163.

133.

Daoussis

Liossis

SNC

Solomou

, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010; 62: 150–158.

134.

Jadon

Sengupta

Nightingale

, et al. Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Res Ther 2017; 19: 210.

135.

Haroon

Inman

Learch

, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65: 2645–2654.

136.

Maas

Arends

Wink

, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors. PLoS One 2017; 12: e0177231.

137.

Molnar

Scherer

Baraliakos

, et al.; Rheumatologists of the Swiss Clinical Quality Management Program. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. Ann Rheum Dis 2018; 77: 63–69.

138.

Klingberg

Nurkkala

Carlsten

, et al. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014; 41: 1349–1356.

139.

Chen

Lin

DTY

, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006; 45: 414–420.

140.

Vandooren

Kruithof

DTY

, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50: 2942–2953.

141.

Yang

Rihl

, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004; 51: 691–699.

142.

Lorenzin

Ortolan

Felicetti

, et al. Serological biomarkers in early axial spondyloarthritis during 24-months follow up (Italian arm of space study). Front Med (Lausanne) 2019; 6: 177.

143.

Maksymowych

Landewé

Conner-Spady

, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 1846–1853.

144.

Soliman

Labib

el-Tantawi

, et al. Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis. Rheumatol Int 2012; 32: 1711–1720.

145.

Wendling

Cedoz

Racadot

. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Joint Bone Spine 2008; 75: 559–562.

146.

Neidhart

Baraliakos

Seemayer

, et al. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1334–1339.

147.

Munk

Gudmann

Christensen

, et al. Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. Rheumatol Int 2016; 36: 541–549.

148.

Veidal

Larsen

Chen

, et al. MMP-mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem 2012; 45: 541–546.

149.

Huvelle

Bothy

Lepoutre

, et al. Measurement of C-terminal cross-linking telopeptide of type I collagen: evaluation of a new automated assay. Clin Biochem 2013; 46: 1778–1779.

150.

Choi

Kim

Kang

, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 1775–1779.

151.

Franck

Keck

. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 343–346.

152.

Favero

Belluzzi

Frallonardo

, et al. Synovial fluid fetuin-A levels in patients affected by osteoarthritis with or without evidence of calcium crystals. Rheumatology (Oxford) 2019; 58: 729–730.

153.

Tuylu

Sari

Solmaz

, et al. Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo) 2014; 69: 688–693.

154.

Miranda-Filloy

López-Mejías

Genre

, et al. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2013; 31: 365–371.

155.

Kim

Park

, et al. Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol 2012; 31: 1231–1238.

156.

Syrbe

Callhoff

Conrad

, et al. Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumatol 2015; 67: 678–685.

157.

Toussirot

Saas

Deschamps

, et al. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res Ther 2009; 11: R101.

158.

Baerlecken

Nothdorft

Stummvoll

, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2014; 73: 1211–1214.

159.

Baraliakos

Baerlecken

Witte

, et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 2014; 73: 1079–1082.

160.

de Winter

van de Sande

Baerlecken

, et al. Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. Arthritis Res Ther 2018; 20: 38.

161.

Wendling

Cedoz

Racadot

. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 2009; 28: 187–190.

162.

Rosas

Martín-López

Otón

, et al. Practical aspects of biological throughput levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. Reumatol Clin. Epub ahead of print 29 October 2018. DOI: 10.1016/j.reuma.2018.09.006.

163.

Balsa

Lula

Marshall

, et al. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature. Expert Opin Biol Ther 2018; 18: 575–584.

164.

de Vries

Wolbink

Stapel

, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007; 66: 133–134.

165.

Balsa

Sanmarti

Rosas

, et al. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. Rheumatology (Oxford) 2018; 57: 688–693.

166.

Spadaro

Punzi

Marchesoni

, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) 2010; 49: 1107–1111.

167.

Matsumoto

Maeda

Tsuboi

, et al. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40: 389–392.

168.

Ordás

Mould

Feagan

, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635–646.

169.

Baert

Noman

Vermeire

, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601–608.

170.

Wolbink

Vis

Lems

, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711–715.

171.

Vincent

Morand

Murphy

, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165–178.

172.

Deodhar

Gladman

McInnes

, et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. Epub ahead of print 15 June 2019. DOI: 10.3899/jrheum.190116.

173.

Poor

Ulshöfer

Gabriel

, et al. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. Clin Exp Immunol 2019; 196: 259–275.

174.

Hwang

Kim

Jeong

, et al. Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis. Rev Bras Reumatol Engl Ed 2017; 57: 311–319.

175.

Bartelds

Wijbrandts

Nurmohamed

, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817–821.

176.

Jamnitski

Bartelds

Nurmohamed

, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284–288.

177.

Jani

Barton

Warren

, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53: 213–222.

178.

Krzysiek

Breban

Ravaud

, et al.; French Ankylosing Spondylitis Infliximab Network. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009; 61: 569–576.

179.

Marzo-Ortega

McGonagle

Jarrett

, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64: 1568–1575.

180.

Benucci

Gobbi

Bandinelli

, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 2017; 65: 419–422.

An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision

Abstract

Keywords

Introduction

Systemic markers of inflammation

Molecules involved in bone homeostasis

Miscellaneous

Anti-drug antibodies and drug through levels

Combination of biomarkers

Conclusion

Footnotes

Acknowledgements

Author contributions

Conflict of interest statement

Funding

ORCID iD

References